Description
Vabametkib (ABN401) is an investigational medication currently being studied in clinical trials for certain types of advanced solid tumors, including colorectal cancer. It is being investigated specifically for patients whose tumors show abnormalities (dysregulation) in the c-MET pathway. This pathway involves a protein that helps cancer cells grow and spread. The trial is designed to assess how well Vabametkib works (efficacy), its safety and tolerability, and how the body processes the drug (pharmacokinetics). The trial is in Phase 2, meaning it is testing the drug in a larger group of patients to see if it works and to further evaluate side effects. The trial is currently recruiting participants.
Mechanism of Action
Vabametkib is designed to target the c-MET pathway, which plays a role in the growth and spread of some cancers. The specific way Vabametkib interacts with the c-MET pathway is being studied in clinical trials. The goal is to block signals that promote tumor growth and survival in patients whose tumors rely on this pathway.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.